a Eye Clinic, Department of Biomedical and Clinical Science "L. Sacco" , Luigi Sacco Hospital, University of Milan , Milan , Italy.
b Save Sight Institute , Sydney Hospital and Sydney Eye Hospital, University of Sydney , Sydney , New South Wales , Australia.
Ocul Immunol Inflamm. 2019;27(4):643-650. doi: 10.1080/09273948.2018.1431292. Epub 2018 Feb 22.
: To assess the efficacy and tolerability of interferon (IFN) alpha-2a in post-infectious uveitis secondary to presumed intraocular tuberculosis (IOTB). : Patients with chronic uveitis secondary to presumed IOTB who, after completing an antitubercular treatment, showed poor response to treatments or recurred after tapering oral corticosteroids to ≤7.5 mg/day were enrolled. All patients were treated with IFN alpha-2a subcutaneous injections. Best-corrected visual acuity (BCVA), central retinal thickness (CRT), and inflammatory signs were compared between baseline and follow-up visits up to six months. : Twelve eyes (six patients) were enrolled. Mean BCVA improved from 0.64 ± 0.55 logMAR at baseline to 0.32 ± 0.31 logMAR at 6 months ( = 0.03). Mean CRT decreased from 372 ± 132.2 μm to 274.66 ± 34.9 μm at six months ( = 0.01). Inflammatory signs (vitritis, vasculitis) also decreased overtime. No major complications or tuberculosis reactivations were recorded. : IFN alpha-2a was efficacious and safe in treating chronic post-infectious uveitis secondary to presumed IOTB.
评估干扰素（IFN）α-2a 治疗疑似眼内结核（IOTB）继发感染后葡萄膜炎的疗效和耐受性。
纳入慢性葡萄膜炎继发于疑似 IOTB 的患者，这些患者在完成抗结核治疗后，对治疗反应不佳或在口服皮质类固醇减量至≤7.5mg/天后复发。所有患者均接受 IFNα-2a 皮下注射治疗。比较基线和随访至 6 个月时最佳矫正视力（BCVA）、中心视网膜厚度（CRT）和炎症体征。
共纳入 12 只眼（6 例患者）。平均 BCVA 从基线时的 0.64±0.55logMAR 提高到 6 个月时的 0.32±0.31logMAR（=0.03）。平均 CRT 从 372±132.2μm 下降到 6 个月时的 274.66±34.9μm（=0.01）。炎症体征（葡萄膜炎、血管炎）也随时间逐渐减轻。未记录到严重并发症或结核病再激活。
IFNα-2a 治疗疑似 IOTB 继发感染后慢性葡萄膜炎有效且安全。
